![](https://investorshub.advfn.com/uicon/33199.png?cb=1474042454)
Tuesday, September 21, 2010 3:14:56 PM
Not "USAMRIID" - should read "WRAIR" and "EbolaCide" should read "DengueCide":
[SNIP]
With this funding, the Walter Reed Army Institute of Research (WRAIR) would challenge specially bred mice with all four serotypes of the dengue fever pathogen, apply an anti-viral treatment prepared by NanoViricides, Inc., and measure the results. Assuming favorable results in these trials, WRAIR would challenge nonhuman primates with varying amounts and serotypes of Dengue pathogen and then treat with varying dose levels of anti-viral treatment. WRAIR would also arrange and implement toxicity experiments on the NanoViricides, Inc. drug candidates. WRAIR would analyze the results so as to determine the value of filing an Investigational New Drug (IND) application and readying drug candidates for human trials.
NanoViricides, Inc. would be the nongovernment recipient of this funding. The company would receive these funds through a contract with WRAIR, which would manage the Department of Defense dollars. The dollars would be spent partly by WRAIR to cover overhead, lab tech and specialist time. NanoViricides, Inc. would be compensated for its expertise, a certain amount of overhead, bench time preparing the drugs and the actual NanoViricides, Inc. drug materials.
This research, if successful, would provide a direct benefit to active-duty, reserve and national guard troops stationed in Puerto Rico and to troops deployed to the various regions of the world where Dengue is endemic. An effective drug would obviously also have major benefits for the civilian population in Puerto Rico.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=54387176
http://www.pierluisi.house.gov/PDF/appropriations/2010/Pierluisi2010AppropriationsRequests.pdf
So......WRAIR and/or Eva for a DengueCide FDA sponsorship at the FDA.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM